{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03713424",
            "orgStudyIdInfo": {
                "id": "2022247"
            },
            "organization": {
                "fullName": "University of Missouri-Columbia",
                "class": "OTHER"
            },
            "briefTitle": "An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction",
            "officialTitle": "An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction",
            "therapeuticArea": [
                "Other"
            ],
            "study": "an-fmri-study-of-the-effects-of-clavulanic-acid-on-drug-addiction"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-03-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-10-17",
            "studyFirstSubmitQcDate": "2018-10-17",
            "studyFirstPostDateStruct": {
                "date": "2018-10-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-28",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Brett Froeliger",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Missouri-Columbia"
            },
            "leadSponsor": {
                "name": "University of Missouri-Columbia",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study."
        },
        "conditionsModule": {
            "conditions": [
                "Tobacco Use Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Clav",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "4-day 125 bid oral capsule administration",
                    "interventionNames": [
                        "Drug: Clavulanic Acid"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "4-day, twice-daily oral capsule administration",
                    "interventionNames": [
                        "Drug: Placebo oral capsule"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Clavulanic Acid",
                    "description": "Beta lactamase inhibitor for smoking cessation",
                    "armGroupLabels": [
                        "Clav"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo oral capsule",
                    "description": "placebo",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Cigarette Smoking",
                    "description": "Biochemical smoking assessment (breath carbon monoxide) at each study visit.",
                    "timeFrame": "5 days"
                },
                {
                    "measure": "Self Reported Side Effects",
                    "description": "Number of reported side effects",
                    "timeFrame": "5 Days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Magnitude of change in BOLD fMRI brain response to smoking related images",
                    "description": "Measure the effects of Clavulanic Acid on fMRI BOLD response to images (change from baseline to end of study) while participants undergo functional magnetic resonance imaging",
                    "timeFrame": "4 days"
                },
                {
                    "measure": "Magnitude of change in resting-stated fMRI brain connectivity",
                    "description": "Measure the effects of Clavulanic Acid on resting-state functional connectivity (change from baseline to end of study) while participants undergo functional magnetic resonance imaging.",
                    "timeFrame": "4 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Entry criteria:\n\nInclusion Criteria all subjects:\n\n1. Age 18-65 years\n2. English fluency\n3. Functional vision (with corrective lenses as needed) to complete assigned assessments and tasks\n4. Smoke \\> 10 cigarettes/day for a minimum of 2 yrs. and have an expired carbon monoxide (CO) concentration of \u2265 10 ppm (to confirm inhalation at screening and scanning)\n5. If female, provide a negative urine pregnancy test.\n6. Agrees to refrain from all other tobacco (i.e., dip/chew, cigars, cigarillos) and/or nicotine products (i.e., e-cigs, patches, gum/lozenges, inhalers/sprays) for the duration of study participation\n\nExclusion Criteria all subjects:\n\n1. Sensitivity or allergy to clavulanic acid/antibiotics\n2. Past head injury or primary neurological disorder associated with MRI abnormalities, including dementia, MCI, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases\n3. Any physical or intellectual disability affecting completion of assessments\n4. Any contraindication to MRI\n5. Use of antidepressants medications with smoking cessation efficacy\n6. Presence of an untreated illness or serious medical condition\n7. Current or past psychosis\n8. Electroconvulsive therapy in last 6 months\n9. Positive pregnancy test (Urine pregnancy testing at screening and prior to fMRI scan) or currently breast feeding or BAC greater than 0.0\n10. Use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous if taken with CLAV) within 14 days of study participation\n11. Abnormal liver function determined by Complete Metabolic Panel - liver enzymes outside normal ranges of AST (SGOT) 5-40 unites/L and ALT( SGPT) 7-56units/L\n12. Abnormal renal function determined by Complete Metabolic Panel - outside normal ranges of BUN 6-24 mg /dl and Creatinine level 0.6 -1.2 mg /dl male, 0.5-1.1mg /dl female\n13. Any other condition or concern that in the investigator's opinion would impact participant safety, compliance with study instructions, or potentially confound the interpretation of the study results",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Madhura Athreya, MS",
                    "role": "CONTACT",
                    "phone": "573-882-2977",
                    "email": "athreyam@health.missouri.edu"
                },
                {
                    "name": "Brett E Froeliger, PhD",
                    "role": "CONTACT",
                    "phone": "573-882-4785",
                    "email": "froeligerb@health.missouri.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Brett Froeliger, PhD",
                    "affiliation": "University of Missouri-Columbia",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Missouri - Columbia",
                    "status": "RECRUITING",
                    "city": "Columbia",
                    "state": "Missouri",
                    "zip": "65211",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brett Froeliger, PhD",
                            "role": "CONTACT",
                            "phone": "513-882-4785",
                            "email": "froeligerb@health.missouri.edu"
                        },
                        {
                            "name": "Madhura Athreya, MS",
                            "role": "CONTACT",
                            "phone": "573-882-2977",
                            "email": "athreyam@health.missouri.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.95171,
                        "lon": -92.33407
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014029",
                    "term": "Tobacco Use Disorder"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16785",
                    "name": "Tobacco Use Disorder",
                    "asFound": "Tobacco Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19100",
                    "name": "Behavior, Addictive",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "asFound": "Drug Addiction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002969",
                    "term": "Clavulanic Acids"
                },
                {
                    "id": "D000019818",
                    "term": "Clavulanic Acid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000065093",
                    "term": "beta-Lactamase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6204",
                    "name": "Clavulanic Acids",
                    "asFound": "Substance abuse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21710",
                    "name": "Clavulanic Acid",
                    "asFound": "Substance abuse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30450",
                    "name": "beta-Lactamase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}